Cantex Pharmaceuticals, Inc. is dedicated to its mission to develop proprietary compounds that improve the treatment of cancer and other life-threatening disorders. As CEO, I am leading Cantex to capitalize on what I believe are multiple opportunities to address significant unmet medical needs in the treatment of malignant and life-threatening diseases.
Cantex’s core strategy is to modify and repurpose existing drugs and, by doing so, create novel, proprietary, safer and more effective therapeutics for cancer and other life-threatening disorders. Through proprietary modifications of known and well-characterized drugs with proven safety profiles and a strong rationale for efficacy, Cantex is able to achieve a dramatically de-risked development pipeline with reduced time to regulatory approvals.
The experience, knowledge and creativity of Cantex’s management team permits us to identify and develop compounds with great therapeutic potential. For example, Cantex targets mechanisms by which cancer is resistant to available treatments, as well as inflammatory processes which worsen outcome after severe traumatic brain injury.
CX-02, our proprietary combination of disulfiram + copper, is highly active in pre-clinical studies with direct cancer cell killing effects against a broad range of cancers, including glioblastoma (a highly malignant brain tumor), prostate cancer, and breast cancer. Based upon the results of completed Phase I clinical trials, extensive pre-clinical data, and ready passage across the blood brain barrier:
Clinical and pre-clinical studies have indicated the potential of Cantex’s other clinical stage product, CX-01, to increase the therapeutic effect of cancer chemotherapy. To date, the Company has completed an open-label, non-randomized Phase IIA clinical trial in acute myeloid leukemia (AML) where CX-01 was administered in combination with chemotherapy.
Cantex’s Executive Chairman, Neil Flanzraich, and I have strong records of developing successful products and companies. We believe that Cantex has the necessary expertise, talent, and determination to develop medicines which significantly benefit patients with cancer and other serious and life-threatening illnesses.
Stephen G. Marcus, M.D.
Chief Executive Officer
Cantex Pharmaceuticals, Inc.